Environmental pressures are known as a driving force behind many of the major animal developmental transitions, such as the switch from tadpoles in the pond to a frog's life on land with legs. Yet the mechanisms behind this physical and environmental relationship remain somewhat of a mystery. Published in Science Advances, a new multi-year study sheds light on the mechanistic link between environmental variation and developmental adaptability. Using a common reef fish as a model, the researchers explored how environmental differences impacted thyroid hormone signaling, a process essential for development regulation.

ARDD 2026 has announced that Thomas Marron, AVP, Emerging Innovation and Strategic Growth at Eli Lilly, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

Verheij syndrome is a rare genetic disorder caused by the impairment of splicing, a critical process in RNA processing. Using the model organism Caenorhabditis elegans, researchers at the Max Planck Institute for Biology of Ageing have now demonstrated that this disruption affects metabolic pathways that rely on vitamin B12. Administering vitamin B12 restored key metabolic processes in the worm model and corrected developmental anomalies in the mutated animals. Analyses of human cells and blood samples from patients revealed comparable metabolic changes. These findings could pave the way for targeted therapies for Verheij syndrome.

ARDD 2026 has announced that Kevin Duffin, VP, Aging Research at Eli Lilly, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Ruth Gimeno, VP Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development at Eli Lilly, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

A new study led by an Iowa State University evolutionary biologist suggests an antenna-like cellular sensor that’s a growing focus in human health could play a central role in how turtles become male or female, which in most species is based on incubation temperature.

Understanding how heart muscle cells stop dividing and acquire the characteristics needed to sustain lifelong cardiac function remains one of the greatest challenges in cardiovascular biology. Leveraging human induced pluripotent stem (iPS) cell technology, a team led by Associate Professor Yoshinori Yoshida (Department of Clinical Application, CiRA, Kyoto University) and Associate Professor Antonio Lucena-Cacace  (WPI-PRIMe, The University of Osaka) has identified PRDM16 as an important regulator governing the balance between proliferation and maturation in human iPSC-derived cardiomyocytes.

Diallyl disulfide is an organosulfur compound derived from garlic, and R-carvone is a monoterpenoid derived from spearmint. Researchers processed these compounds into oil-in-water nanoemulsions and applied it to the adzuki bean beetle—a known legume pest. The researchers found that the nanoemulsions were highly toxic against the pest, suggesting that they could be a promising environmentally friendly alternative to synthetic pest-control agents.